Pricing pressure in US to keep pharma cos' growth under check
Pharma companies are likely to report sequentially flat EBITDA growth in 3QFY17, impacted by pricing pressure and higher R&D expenditure, a report said.
Jan 15, 2017, 13:51 PM IST
Pharma companies are likely to report sequentially flat EBITDA growth in 3QFY17, impacted by pricing pressure and higher R&D expenditure, a report said.
Jan 15, 2017, 13:51 PM IST